Stock listing
BOATS:AZTR Azitra Inc Stock
US listing (BOATS) of Azitra Inc · home listing NYSE American:AZTR
Follow Azitra Inc into a list and get an email when it puts out news.
Home listing price · AMEX:AZTR
$0.517 USD -0.053 (-9.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, AMEX:AZTR
- Day range
- $0.509 – $0.552 USDNov 20, 2026
- Volume
- 56,165 sharesNov 20, 2026
- Market cap
- $3.13M USDAt the close on Nov 20, 2026 · price × 6.06M shares outstanding
- 52-week range
- $0.509 – $3.910 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.73M USDMedian day 8,258 shares · 8 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:AZTR · Home | $0.517 USD | -0.053 (-9.4%) | 56,165 | $0.541 | $0.552 | $0.509 | $0.570 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:AZTR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.517 | -0.053 | -9.4% | $0.541 | $0.552 | $0.509 | 56,165 | |
| $0.570 | -0.038 | -6.2% | $0.587 | $0.605 | $0.570 | 27,830 | |
| $0.608 | -0.019 | -3.0% | $0.627 | $0.627 | $0.584 | 31,780 | |
| $0.627 | +0.019 | +3.1% | $0.597 | $0.652 | $0.560 | 160,378 | |
| $0.608 | -0.060 | -9.0% | $0.660 | $0.670 | $0.608 | 77,105 | |
| $0.669 | +0.083 | +14.2% | $0.566 | $0.690 | $0.561 | 215,847 | |
| $0.585 | -0.015 | -2.5% | $0.600 | $0.619 | $0.585 | 68,841 | |
| $0.600 | -0.044 | -6.8% | $0.665 | $0.690 | $0.600 | 149,079 | |
| $0.644 | -0.089 | -12.1% | $0.724 | $0.724 | $0.644 | 190,125 | |
| $0.733 | +0.007 | +1.0% | $0.749 | $0.780 | $0.719 | 95,558 | |
| $0.725 | -0.091 | -11.1% | $0.800 | $0.811 | $0.710 | 176,795 | |
| $0.816 | -0.068 | -7.7% | $0.857 | $0.857 | $0.795 | 133,783 | |
| $0.884 | +0.047 | +5.7% | $0.792 | $0.950 | $0.780 | 337,873 | |
| $0.836 | +0.067 | +8.8% | $0.769 | $0.900 | $0.740 | 522,730 | |
| $0.769 | +0.012 | +1.6% | $0.712 | $0.790 | $0.651 | 783,000 | |
| $0.757 | -0.148 | -16.4% | $0.863 | $0.873 | $0.732 | 1,128,700 | |
| $0.905 | -0.215 | -19.2% | $1.090 | $1.110 | $0.860 | 2,687,700 | |
| $1.120 | -0.410 | -26.8% | $1.210 | $1.320 | $1.050 | 7,835,100 | |
| $1.530 | +0.810 | +112.5% | $1.040 | $2.130 | $0.906 | 148,420,100 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | 0.000 | 0.0% | $0.720 | $0.720 | $0.720 | 0 | |
| $0.720 | -0.460 | -39.0% | $1.210 | $1.210 | $0.520 | 26,706 | |
| $1.180 | -0.120 | -9.2% | $1.300 | $1.320 | $1.160 | 4,721 | |
| $1.300 | -0.020 | -1.5% | $1.300 | $1.320 | $1.260 | 3,230 | |
| $1.320 | 0.000 | 0.0% | $1.330 | $1.350 | $1.300 | 2,871 | |
| $1.320 | +0.020 | +1.5% | $1.330 | $1.370 | $1.300 | 2,892 | |
| $1.300 | -0.070 | -5.1% | $1.400 | $1.400 | $1.300 | 4,128 | |
| $1.370 | +0.050 | +3.8% | $1.380 | $1.400 | $1.300 | 6,229 | |
| $1.320 | +0.030 | +2.3% | $1.340 | $1.380 | $1.300 | 8,258 | |
| $1.290 | -0.090 | -6.5% | $1.390 | $1.470 | $1.230 | 14,292 | |
| $1.380 | +0.070 | +5.3% | $1.340 | $1.390 | $1.320 | 6,087 | |
| $1.310 | -0.390 | -22.9% | $1.640 | $1.670 | $1.240 | 32,145 | |
| $1.700 | +0.020 | +1.2% | $1.700 | $1.750 | $1.630 | 6,110 | |
| $1.680 | +0.010 | +0.6% | $1.610 | $1.690 | $1.610 | 1,525 | |
| $1.670 | +0.010 | +0.6% | $1.660 | $1.680 | $1.590 | 6,060 | |
| $1.660 | -0.050 | -2.9% | $1.700 | $1.750 | $1.650 | 8,495 | |
| $1.710 | 0.000 | 0.0% | $1.720 | $1.740 | $1.660 | 2,965 | |
| $1.710 | -0.030 | -1.7% | $1.770 | $1.770 | $1.670 | 6,200 | |
| $1.740 | -0.040 | -2.2% | $1.810 | $1.810 | $1.700 | 11,201 | |
| $1.780 | +0.160 | +9.9% | $1.620 | $1.800 | $1.620 | 5,677 | |
| $1.620 | -0.090 | -5.3% | $1.760 | $1.760 | $1.610 | 11,244 | |
| $1.710 | -0.050 | -2.8% | $1.780 | $1.790 | $1.710 | 4,702 | |
| $1.760 | -0.020 | -1.1% | $1.850 | $1.910 | $1.760 | 13,020 | |
| $1.780 | -0.020 | -1.1% | $1.820 | $1.850 | $1.770 | 2,910 | |
| $1.800 | +0.020 | +1.1% | $1.780 | $1.880 | $1.730 | 5,701 | |
| $1.780 | +0.060 | +3.5% | $1.710 | $1.830 | $1.690 | 5,995 | |
| $1.720 | -0.080 | -4.4% | $1.750 | $1.790 | $1.720 | 2,860 | |
| $1.800 | 0.000 | 0.0% | $1.780 | $1.800 | $1.700 | 3,303 | |
| $1.800 | -0.010 | -0.6% | $1.760 | $1.820 | $1.750 | 3,004 | |
| $1.810 | +0.040 | +2.3% | $1.710 | $1.830 | $1.690 | 5,274 | |
| $1.770 | +0.020 | +1.1% | $1.730 | $1.780 | $1.710 | 3,702 | |
| $1.750 | -0.020 | -1.1% | $1.730 | $1.770 | $1.690 | 6,441 | |
| $1.770 | -0.090 | -4.8% | $1.820 | $1.890 | $1.710 | 10,319 | |
| $1.860 | +0.130 | +7.5% | $1.740 | $1.890 | $1.650 | 24,337 | |
| $1.730 | +0.150 | +9.5% | $1.570 | $1.840 | $1.530 | 51,083 | |
| $1.580 | +0.080 | +5.3% | $1.590 | $1.650 | $1.470 | 49,156 | |
| $1.500 | +0.170 | +12.8% | $1.320 | $1.600 | $1.280 | 277,254 | |
| $1.330 | +0.060 | +4.7% | $1.350 | $1.410 | $1.300 | 20,003 | |
| $1.270 | +0.020 | +1.6% | $1.300 | $1.300 | $1.260 | 4,784 |
Splits
3 splits since 2024 · AMEX:AZTR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 3-for-20 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- BOATS:AZTR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 30 slides
Latest news
Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
Nov 12, 2026
Closed $0.608 (-9.0%) on Nov 13, 2026
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
Nov 10, 2026
Closed $0.60 (-6.8%) on Nov 10, 2026
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
Oct 29, 2026
Closed $0.757 (-16.4%) on Oct 29, 2026
Azitra, Inc. Announces Reverse Stock Split
Oct 16, 2026
Closed $0.72 (0.0%) on Oct 16, 2026
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Aug 21, 2026
Closed $1.33 (+4.7%) on Aug 21, 2026
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Aug 12, 2026
Closed $1.40 (+3.7%) on Aug 13, 2026
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Jun 17, 2026
Closed $2.03 (+10.3%) on Jun 17, 2026
Azitra, Inc. to Present at 2026 BIO International Convention
Jun 16, 2026
Closed $2.03 (+10.3%) on Jun 17, 2026
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Jun 4, 2026
Closed $2.11 (-3.2%) on Jun 5, 2026
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
May 27, 2026
Closed $2.05 (-1.0%) on May 28, 2026
Azitra Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 39 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 4 decks · latest August 2026
Where Azitra Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:AZTR · Home listing | NYSE American | United States | USD |
| BOATS:AZTR · This page | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 0.6×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$618,677 USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,063 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.37M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
| Median of the others | US$3.11M | −US$2.53M | −6.8× | 0.6× | −123.7% | 0.0× | 1.46 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.05 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Francisco Salva | President and CEO |
| Norman Staskey | Chief Financial Officer |
| Travis Whitfill | Cofounder and Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Francisco Salva | President and CEO |
| John R. Schroer | Director |
| Travis Whitfill | Cofounder and Chief Operating Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −9.0% |
| Q2 2026 | Aug 12, 2026 | −2.1% |
| Q1 2026 | May 13, 2026 | −15.9% |
| Q4 2025 | Feb 27, 2026 · After close | −6.3% |
| Q3 2025 | Nov 12, 2025 · After close | −14.6% |
| Q2 2025 | Aug 11, 2025 · After close | −7.5% |
| Q1 2025 | May 14, 2025 | +0.4% |
| Q4 2024 | Feb 24, 2025 · Before open | −4.3% |
| Q3 2024 | Nov 12, 2024 · After close | −3.7% |
| Q2 2024 | Aug 12, 2024 · After close | +2.9% |
All 13 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −13.3% |
| Q4 2023 | Mar 15, 2024 · After close | 0.0% |
| Q3 2023 | Nov 14, 2023 · After close | −3.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Technical Presentation (2024) | Technical | 18 slides | 2024 |
| Investor Presentation (July 2023) | Investor deck | 26 slides | Jul 7, 2023 |
| Society of Investigative Dermatology Annual Meeting | Conference | 16 slides |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock underlying warrants Update: about US$1.5M · US$0.32 a share · Warrants at US$0.32 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Buyers: Alumni Capital LP | Feb 6, 2026 |
| Common stock (equity line of credit) Tranche closed: US$2.8M raised Buyers: Alumni Capital LP ($2.8M in gross proceeds through the equity line of credit) Use of proceeds: To fund the clinical pipeline | Nov 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Jun 15, 2023.
- Price
- US$5.00 a share
- Shares offered
- 1,500,000 shares of common stock
- Offering size
- US$7.5 million
- Underwriters' option
- Up to 225,000 more shares
- Listing
- AZTR on NYSE American
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Jun 21, 2023
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 15, 2022 |
| Filed publicly | Feb 21, 2023 |
| Amended 6 times | Newest Jun 13, 2023 |
| Shares registered with an exchange | May 16, 2023 |
| Declared effective by the SEC | Jun 15, 2023 |
| Final prospectus, with the price | Jun 21, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2023 |
| EFFECT · Notice that a registration is effective | Jun 15, 2023 |
| CORRESP · Letter to the SEC | Jun 13, 2023 |
| S-1/A · Registration statement, amended | Jun 13, 2023 |
| CORRESP · Letter to the SEC | Jun 13, 2023 |
| CORRESP · Letter to the SEC | Jun 13, 2023 |
| UPLOAD · Letter from the SEC | Jun 13, 2023 |
| FWP · Free writing prospectus | Jun 5, 2023 |
| S-1/A · Registration statement, amended | Jun 5, 2023 |
| CORRESP · Letter to the SEC | May 31, 2023 |
All 35 filings
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 7.50K | 686.0K | 284.0K | 110.0K | |
| Cost of revenue | 453.1K | 448.2K | 425.5K | 406.0K | 84.8K | |
| Gross profit | -453.1K | 7.50K | 686.0K | 284.0K | 110.0K | |
| Research and development | 4.84M | 4.72M | 3.64M | 6.10M | 5.38M | |
| Selling, general and administrative | 6.13M | 6.27M | 4.49M | 3.64M | 3.95M | |
| Operating income | -11.0M | -11.0M | -7.45M | -9.45M | -9.22M | |
| Depreciation and amortization | 138.1K | 131.2K | 129.7K | 125.9K | 84.8K | 57.0K |
| EBITDA | -10.8M | -10.9M | -7.32M | -9.33M | -9.14M | |
| Interest expense | 7.59K | 12.2K | 167.7K | 251.9K | 67.0K | |
| Income before tax | -10.9M | -8.96M | -11.3M | -10.7M | -8.94M | |
| Income tax | 8.32K | 9.03K | 17.3K | -727.8K | 174.4K | |
| Net income | -11.0M | -8.97M | -11.3M | -10.7M | -8.94M | |
| Earnings per share, basic | -2.25 | -15.70 | -54.98 | -12.74 | -147.78 | |
| Earnings per share, diluted | -2.25 | -15.70 | -54.98 | -12.74 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 2.07M | 4.55M | 1.80M | 3.49M | 8.04M | |
| Short-term investments | -4.55B | |||||
| Receivables | 912 | 233 | 223.5K | 175.0K | 334.2K | 528.4K |
| Inventory | -215.2K | 216.9K | ||||
| Current assets | 3.02M | 5.23M | 2.54M | 4.14M | 8.49M | 16.6M |
| Property, plant and equipment | 548.6K | 654.0K | 710.1K | 847.0K | 946.7K | 582.4K |
| Goodwill | 246.2M | |||||
| Total assets | 5.03M | 7.36M | 5.12M | 7.17M | 10.2M | |
| Accounts payable | 399.4K | 490.3K | 897.3K | 784.7K | 717.8K | 417.4K |
| Current liabilities | 1.07M | 1.38M | 1.60M | 2.22M | 1.21M | 1.00M |
| Long-term debt | 6.60M | 992.0K | ||||
| Total debt | 422.1K | 555.5K | 885.9K | 7.73M | 992.0K | |
| Total liabilities | 1.22M | 1.66M | 2.20M | 9.73M | 36.0M | |
| Shareholders' equity | 3.80M | 5.70M | 2.91M | -36.3M | -25.8M | |
| Shares outstanding | 1.07M | 1.15M | 403.2K | 1.04M | 60.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -11.2M | -10.2M | -7.36M | -8.35M | -8.07M | -6.54M |
| Capital spending | -24.2K | -8.57K | -26.5K | -33.1K | -652.3K | -217.7K |
| Free cash flow | -11.2M | -10.2M | -7.39M | -8.38M | -8.72M | -6.76M |
| Cash from investing | -182.9K | -379.2K | -318.3K | -336.8K | -652.3K | -541.0K |
| Cash from financing | 8.92M | 13.3M | 5.98M | 4.13M | 992.9K | 16.6M |
| Change in cash | -2.49M | 2.76M | -1.70M | -4.55M | -7.73M | 9.47M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B5 · Prospectus | Sep 28, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 4, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 29, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | May 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | May 21, 2026 | Offer document | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 8, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | May 8, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Mar 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 5, 2026 | Current report | SEC |
| 8-K · Current report | Feb 27, 2026 | Results | SEC |
| 10-K · Annual report | Feb 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Feb 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 30, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Jan 2, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 19, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 16, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 10, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 1, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 25, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| RW · Request to withdraw a registration | Oct 14, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| S-1 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 29, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Jul 24, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 3, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | May 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 19, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | May 2, 2025 | Offer document | SEC |
| 8-K · Current report | May 2, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 30, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 28, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 24, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Apr 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 31, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Mar 5, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 24, 2025 | Results | SEC |
| 10-K · Annual report | Feb 24, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 6, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 16, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jan 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 14, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 26, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Oct 9, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 9, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 2, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 1, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jul 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 26, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jul 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 23, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 19, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | Jul 15, 2024 | Offer document | SEC |
| S-1 · Registration statement | Jul 15, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 9, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jul 5, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 5, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 3, 2024 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jul 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 1, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jun 14, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Jun 3, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 24, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 15, 2024 | Results | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| SC 13G · Big-stake notice | Feb 27, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 26, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Feb 15, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Feb 12, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| FWP · Free writing prospectus | Jan 19, 2024 | Offer document | SEC |
| S-1 · Registration statement | Jan 19, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 11, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jan 4, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 4, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 24, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 11, 2023 | Management or board change | SEC |
| 8-K · Current report | Jul 7, 2023 | Current report | SEC |
| SC 13D · Big-stake notice | Jul 3, 2023 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jun 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2023 | Material contract | SEC |
| 424B4 · Prospectus | Jun 21, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 16, 2023 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 15, 2023 | Insider trade | SEC |
This page holds 200 of 242 filings. Open Filings
Cap table
Built by 6ix from Azitra Inc’s releases · as of Nov 12, 2026
- Common shares
- 6,060,435
- Fully diluted
- 6,060,435
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,060,435 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 6,060,435 |
| Oct 16, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Barbara Ryan Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Supernus Pharmaceuticals, Inc. (Director · Since at least Jan 1, 2026); MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); INVO Fertility, Inc. (Director · Since at least Sep 14, 2020) | Director · Since at least Jun 15, 2023 |
| John Schroer Other companies: Alumis Inc. (Chief Financial Officer · Since at least Jun 27, 2024); Translate Bio Inc (See Remarks · Jun 27, 2018 – Jun 27, 2018 · Past) | Director · Since at least Jun 15, 2023 |
| Francisco Salva Other companies: Vincerx Pharma Inc (Director · May 13, 2021 – May 23, 2024 · Past) | President and CEO · Since at least Jun 15, 2023 |
| Norman Staskey Other companies: VivoSim Labs, Inc. (Chief Financial Officer · Since at least Dec 30, 2024) | Chief Financial Officer · Since at least Jun 15, 2023 |
| Travis Whitfill Other companies: IN8bio, Inc. (Director · Jul 29, 2021 – Dec 19, 2024 · Past) | Cofounder and Chief Operating Officer · Since at least Jun 15, 2023 |
| Andrew McClary | Director · Jun 15, 2023 – Jun 23, 2023 · Past |
| John R. Schroer | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Azitra Inc.